vs
Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and Presurance Holdings, Inc. (PRHI). Click either name above to swap in a different company.
Foghorn Therapeutics Inc. is the larger business by last-quarter revenue ($9.2M vs $5.7M, roughly 1.6× Presurance Holdings, Inc.). Foghorn Therapeutics Inc. runs the higher net margin — -234.3% vs -369.2%, a 134.9% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs -61.4%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs -44.7%).
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
FHTX vs PRHI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $5.7M |
| Net Profit | $-21.7M | $-17.0M |
| Gross Margin | — | — |
| Operating Margin | -258.2% | -322.7% |
| Net Margin | -234.3% | -369.2% |
| Revenue YoY | 223.8% | -61.4% |
| Net Profit YoY | -11.1% | 32.9% |
| EPS (diluted) | $-0.35 | $-1.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | $5.7M | ||
| Q3 25 | $8.2M | $6.8M | ||
| Q2 25 | $7.6M | $16.1M | ||
| Q1 25 | $6.0M | $15.9M | ||
| Q4 24 | $2.9M | $14.7M | ||
| Q3 24 | $7.8M | $16.0M | ||
| Q2 24 | $6.9M | $17.9M | ||
| Q1 24 | $5.0M | $18.6M |
| Q4 25 | $-21.7M | $-17.0M | ||
| Q3 25 | $-15.8M | $-4.0M | ||
| Q2 25 | $-17.9M | $2.1M | ||
| Q1 25 | $-18.8M | $522.0K | ||
| Q4 24 | $-19.5M | $-25.4M | ||
| Q3 24 | $-19.1M | $52.8M | ||
| Q2 24 | $-23.0M | $-4.0M | ||
| Q1 24 | $-25.0M | $74.0K |
| Q4 25 | -258.2% | -322.7% | ||
| Q3 25 | -226.9% | -42.7% | ||
| Q2 25 | -279.2% | -22.6% | ||
| Q1 25 | -385.0% | -27.9% | ||
| Q4 24 | -840.5% | -177.1% | ||
| Q3 24 | -305.5% | -45.8% | ||
| Q2 24 | -386.6% | -24.3% | ||
| Q1 24 | -558.3% | 2.7% |
| Q4 25 | -234.3% | -369.2% | ||
| Q3 25 | -194.4% | -58.2% | ||
| Q2 25 | -237.3% | 12.7% | ||
| Q1 25 | -316.4% | 3.3% | ||
| Q4 24 | -682.9% | -172.4% | ||
| Q3 24 | -244.9% | 329.6% | ||
| Q2 24 | -333.6% | -22.1% | ||
| Q1 24 | -495.4% | 0.4% |
| Q4 25 | $-0.35 | $-1.40 | ||
| Q3 25 | $-0.25 | $-0.32 | ||
| Q2 25 | $-0.28 | $0.17 | ||
| Q1 25 | $-0.30 | $0.04 | ||
| Q4 24 | $-0.23 | $-2.08 | ||
| Q3 24 | $-0.31 | $4.32 | ||
| Q2 24 | $-0.45 | $-0.32 | ||
| Q1 24 | $-0.59 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.9M | $52.1M |
| Total DebtLower is stronger | — | $12.2M |
| Stockholders' EquityBook value | $-108.5M | $9.0M |
| Total Assets | $198.1M | $239.3M |
| Debt / EquityLower = less leverage | — | 1.36× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.9M | $52.1M | ||
| Q3 25 | $89.3M | $62.3M | ||
| Q2 25 | $72.6M | $58.3M | ||
| Q1 25 | $61.0M | $52.3M | ||
| Q4 24 | $55.5M | $48.8M | ||
| Q3 24 | $57.7M | $53.6M | ||
| Q2 24 | $138.9M | $33.0M | ||
| Q1 24 | $79.3M | $41.0M |
| Q4 25 | — | $12.2M | ||
| Q3 25 | — | $12.1M | ||
| Q2 25 | — | $12.1M | ||
| Q1 25 | — | $12.0M | ||
| Q4 24 | — | $11.9M | ||
| Q3 24 | — | $16.5M | ||
| Q2 24 | — | $24.8M | ||
| Q1 24 | — | $24.9M |
| Q4 25 | $-108.5M | $9.0M | ||
| Q3 25 | $-89.7M | $25.3M | ||
| Q2 25 | $-76.7M | $28.2M | ||
| Q1 25 | $-61.7M | $25.6M | ||
| Q4 24 | $-45.5M | $21.5M | ||
| Q3 24 | $-28.3M | $49.1M | ||
| Q2 24 | $-14.3M | $-1.2M | ||
| Q1 24 | $-97.5M | $2.6M |
| Q4 25 | $198.1M | $239.3M | ||
| Q3 25 | $205.0M | $285.0M | ||
| Q2 25 | $226.2M | $283.3M | ||
| Q1 25 | $258.7M | $277.1M | ||
| Q4 24 | $284.0M | $281.7M | ||
| Q3 24 | $308.4M | $299.9M | ||
| Q2 24 | $328.6M | $292.9M | ||
| Q1 24 | $255.0M | $301.1M |
| Q4 25 | — | 1.36× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.47× | ||
| Q4 24 | — | 0.55× | ||
| Q3 24 | — | 0.34× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 9.75× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-22.3M | $-43.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-22.3M | $-43.9M | ||
| Q3 25 | $-18.9M | $-681.0K | ||
| Q2 25 | $-21.0M | $-2.8M | ||
| Q1 25 | $-24.0M | $-15.3M | ||
| Q4 24 | $-24.5M | $-32.7M | ||
| Q3 24 | $-21.0M | $-10.7M | ||
| Q2 24 | $-25.5M | $-10.1M | ||
| Q1 24 | $-29.3M | $8.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-21.0M | — | ||
| Q1 25 | $-24.0M | — | ||
| Q4 24 | $-25.0M | — | ||
| Q3 24 | $-21.3M | — | ||
| Q2 24 | $-25.6M | — | ||
| Q1 24 | $-29.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -278.2% | — | ||
| Q1 25 | -403.2% | — | ||
| Q4 24 | -875.3% | — | ||
| Q3 24 | -273.0% | — | ||
| Q2 24 | -371.0% | — | ||
| Q1 24 | -583.1% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 16.8% | — | ||
| Q3 24 | 4.0% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 2.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.34× | ||
| Q1 25 | — | -29.23× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.20× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 110.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
